| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Magnesium hydroxide [laxative] |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
|
| Magnesium hydroxide mixture BP |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
|
| Product containing precisely magnesium hydroxide 83 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
|
| Product containing magnesium hydroxide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
1 |
| Liquid paraffin+magnesium hydroxide oral emulsion BP |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
|
| Product containing aluminium hydroxide and magnesium hydroxide and simeticone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Aluminium hydroxide 600 mg and magnesium hydroxide 300 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
|
| Dried aluminium hydroxide gel 44 mg/mL and magnesium hydroxide 39 mg/mL oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
|
| Dried aluminium hydroxide gel 120 mg/mL and magnesium hydroxide 60 mg/mL oral suspension |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
|
| Product containing calcium carbonate and famotidine and magnesium hydroxide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
3 |
| Calcium carbonate 800 mg and famotidine 10 mg and magnesium hydroxide 165 mg chewable tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
|
| Product containing aluminium hydroxide and magnesium hydroxide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Product containing magnesium hydroxide and mineral oil (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Product containing activated charcoal and magnesium hydroxide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Product containing aluminium oxide and magnesium hydroxide and oxetacaine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Product containing magnesium hydroxide and omeprazole and sodium bicarbonate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
3 |
| Product containing precisely magnesium hydroxide 700 milligram and omeprazole 20 milligram and sodium bicarbonate 600 milligram/1 each conventional release chewable tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
|
| Product containing precisely magnesium hydroxide 700 milligram and omeprazole 40 milligram and sodium bicarbonate 600 milligram/1 each conventional release chewable tablet (clinical drug) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
|
| Omeprazole 20mg + sodium bicarbonate 750mg + magnesium hydroxide 343 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
|
| Omeprazole 40mg + sodium bicarbonate 750mg + magnesium hydroxide 343 mg tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
|
| Aluminium hydroxide 600 mg and magnesium hydroxide 300 mg oral tablet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
1 |
| Aluminium hydroxide 600 mg and magnesium hydroxide 300 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
1 |
| Aluminium hydroxide 600 mg and magnesium hydroxide 300 mg oral tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Aluminium hydroxide 600 mg and magnesium hydroxide 300 mg oral tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Product containing aluminium hydroxide and magnesium hydroxide in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Product containing precisely magnesium hydroxide 83 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely magnesium hydroxide 83 milligram/1 milliliter conventional release oral suspension (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
1 |
| Dried aluminium hydroxide gel 120 mg/mL and magnesium hydroxide 60 mg/mL oral suspension |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Dried aluminium hydroxide gel 120 mg/mL and magnesium hydroxide 60 mg/mL oral suspension |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Dried aluminium hydroxide gel 44 mg/mL and magnesium hydroxide 39 mg/mL oral suspension |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
False |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Dried aluminium hydroxide gel 44 mg/mL and magnesium hydroxide 39 mg/mL oral suspension |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Magnesium hydroxide-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
1 |
| Dried aluminium hydroxide gel- and magnesium hydroxide-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
1 |
| Product containing dried aluminium hydroxide gel and magnesium hydroxide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
1 |
| Aluminium oxide and magnesium hydroxide and oxetacaine only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Aluminium hydroxide and magnesium hydroxide only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Product containing only aluminium hydroxide and magnesium hydroxide and simeticone (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Product containing only activated charcoal and magnesium hydroxide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Calcium carbonate and famotidine and magnesium hydroxide only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
3 |
| Product containing only dried aluminium hydroxide gel and magnesium hydroxide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
1 |
| Magnesium hydroxide only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
1 |
| Product containing only magnesium hydroxide and mineral oil (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Product containing only magnesium hydroxide and omeprazole and sodium bicarbonate (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
3 |
| Aluminium hydroxide and magnesium hydroxide only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Magnesium hydroxide only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
1 |
| Product containing only dried aluminium hydroxide gel and magnesium hydroxide in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
1 |
| Magnesium hydroxide- and omeprazole- and sodium bicarbonate-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
3 |
| Product containing only magnesium hydroxide and omeprazole and sodium bicarbonate in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
3 |
| Product containing precisely magnesium hydroxide 700 milligram and omeprazole 20 milligram and sodium bicarbonate 600 milligram/1 each conventional release chewable tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
3 |
| Product containing precisely magnesium hydroxide 700 milligram and omeprazole 20 milligram and sodium bicarbonate 600 milligram/1 each conventional release chewable tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
3 |
| Product containing only calcium carbonate and famotidine and magnesium hydroxide in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
3 |
| Calcium carbonate 800 mg and famotidine 10 mg and magnesium hydroxide 165 mg chewable tablet |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
3 |
| Calcium carbonate 800 mg and famotidine 10 mg and magnesium hydroxide 165 mg chewable tablet |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
3 |
| Calcium carbonate- and famotidine- and magnesium hydroxide-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
3 |
| Product containing precisely magnesium hydroxide 700 milligram and omeprazole 40 milligram and sodium bicarbonate 600 milligram/1 each conventional release chewable tablet (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
3 |
| Product containing precisely magnesium hydroxide 700 milligram and omeprazole 40 milligram and sodium bicarbonate 600 milligram/1 each conventional release chewable tablet (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
3 |
| Product containing only aluminium hydroxide and dimeticone and magnesium hydroxide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Dried aluminium hydroxide gel 44 mg/mL and magnesium hydroxide 39 mg/mL oral suspension |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
1 |
| Dried aluminium hydroxide gel 44 mg/mL and magnesium hydroxide 39 mg/mL oral suspension |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
1 |
| Dried aluminium hydroxide gel 120 mg/mL and magnesium hydroxide 60 mg/mL oral suspension |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
1 |
| Dried aluminium hydroxide gel 120 mg/mL and magnesium hydroxide 60 mg/mL oral suspension |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
1 |
| Magnesium hydroxide 750 microliter/mL and mineral oil 250 microliter/mL oral emulsion |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Magnesium hydroxide 750 microliter/mL and mineral oil 250 microliter/mL oral emulsion |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Magnesium hydroxide- and mineral oil-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Product containing only magnesium hydroxide and mineral oil in oral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Magnesium hydroxide 750 microlitre/mL and mineral oil 250 microlitre/mL oral suspension |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Magnesium hydroxide 750 microlitre/mL and mineral oil 250 microlitre/mL oral suspension |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Aluminium hydroxide 58.2 mg/mL and magnesium hydroxide 19.6 mg/mL and oxetacaine 2 mg/mL oral suspension |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
3 |
| Aluminium hydroxide 58.2 mg/mL and magnesium hydroxide 19.6 mg/mL and oxetacaine 2 mg/mL oral suspension |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
3 |
| Aluminium hydroxide- and magnesium hydroxide- and oxetacaine-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Aluminium hydroxide and magnesium hydroxide and oxetacaine only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Product containing only aluminium hydroxide and magnesium hydroxide and oxetacaine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
3 |
| Product containing aluminium hydroxide and magnesium hydroxide and oxetacaine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
3 |
| Product containing precisely aluminium hydroxide 35 milligram/1 milliliter and magnesium hydroxide 40 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Product containing precisely aluminium hydroxide 35 milligram/1 milliliter and magnesium hydroxide 40 milligram/1 milliliter conventional release oral suspension (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Product containing precisely aluminium hydroxide 35 milligram/1 milliliter and magnesium hydroxide 40 milligram/1 milliliter and simeticone 5 milligram/1 milliliter conventional release oral suspension (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Product containing precisely aluminium hydroxide 35 milligram/1 milliliter and magnesium hydroxide 40 milligram/1 milliliter and simeticone 5 milligram/1 milliliter conventional release oral suspension (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Aluminium hydroxide and magnesium hydroxide and simeticone only product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Aluminium hydroxide- and magnesium hydroxide- and simeticone-containing product in oral dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
| Aluminium hydroxide- and dimeticone- and magnesium hydroxide-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Magnesium hydroxide (substance) |
Inferred relationship |
Some |
2 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]